WO2022248459A1 - Utilisation d'ascorbyl glucoside pour prévenir la coloration de points noirs - Google Patents

Utilisation d'ascorbyl glucoside pour prévenir la coloration de points noirs Download PDF

Info

Publication number
WO2022248459A1
WO2022248459A1 PCT/EP2022/064027 EP2022064027W WO2022248459A1 WO 2022248459 A1 WO2022248459 A1 WO 2022248459A1 EP 2022064027 W EP2022064027 W EP 2022064027W WO 2022248459 A1 WO2022248459 A1 WO 2022248459A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
ascorbyl glucoside
skin
cosmetic
colour
Prior art date
Application number
PCT/EP2022/064027
Other languages
English (en)
Inventor
Julia PUECH
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2022248459A1 publication Critical patent/WO2022248459A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C

Definitions

  • the present invention relates to the field of cosmetic products, which are more particularly intended for the prevention of cutaneous blackheads, in particular for inhibiting the appearance of the black or brown colour of comedones.
  • the present invention is targeted at providing the non-therapeutic cosmetic use of a specific active agent as inhibitor of the black or brown colouration of comedones.
  • It also relates to a non-therapeutic cosmetic process for reducing and/or inhibiting the development of colour, for example brown or black colour, of cutaneous comedones and/or preventing the appearance of cutaneous blackheads, comprising the topical application to the skin of a composition comprising said active agent.
  • a non-therapeutic cosmetic process for reducing and/or inhibiting the development of colour, for example brown or black colour, of cutaneous comedones and/or preventing the appearance of cutaneous blackheads, comprising the topical application to the skin of a composition comprising said active agent.
  • the term “skin” is understood to denote all of the skin of the body, excluding the scalp and the mucous membranes.
  • skin is targeted at the skin of the face and/or of the hands, in particular the skin of the face, more particularly the skin of the forehead and/or of the alae of the nose and/or of the chin.
  • the source of the colour of the cutaneous blackhead has not been fully established. It is, on the other hand, known that the cutaneous blackhead results from the process of comedogenesis which affects pilosebaceous units of sebaceous follicle type, which are distributed predominantly on the face.
  • a cutaneous blackhead is thus an open comedo (non inflammatory lesion) characterized by distension of the hair canal, sebum retention and excessive comification of the pilosebaceous duct. Hypercornification would result in sebum retention and in the accumulation of cell debris.
  • a certain number of solutions for treating cutaneous blackheads have already been provided. Some of these solutions are based more particularly on the treatment of the blackheads with an active agent capable of preventing, altering or eliminating the blackheads.
  • active agents capable of dissolving the lipids constituting the blackheads such as the alkyl lactate derivatives described in the patent US 4 540567, the lipase enzyme, described in the application US 2006/051339, or else the neutralized fatty acids as described in the application EP 3 150 187.
  • active agents capable of dissolving the lipids constituting the blackheads such as the alkyl lactate derivatives described in the patent US 4 540567, the lipase enzyme, described in the application US 2006/051339, or else the neutralized fatty acids as described in the application EP 3 150 187.
  • these active agents have the drawback of impairing the organoleptic properties of the composition comprising them, in particular the odour and/or the colour of the composition, over time.
  • active agents also prove to be effective with regard to blackheads that have already appeared.
  • this relies on the use, for example, of a comedo suction device, a comedo extractor, or self-adhesive patches to be removed after a few minutes of contact with the skin. It clearly has the drawbacks of being painful and of generating redness or irritation.
  • a subject of the present invention is very particularly that of proposing novel active agents that are effective with regard to blackheads but are free from the above-mentioned drawbacks.
  • the treatment of cutaneous blackheads involves the reduction or indeed even the inhibition of the development of the black or brown color of the comedones and/or the prevention of the appearance of the cutaneous blackheads.
  • the present invention relates to the cosmetic use of ascorbyl glucoside and also its solvates for reducing and/or inhibiting the development of colour, for example brown or black colour, of cutaneous comedones.
  • ascorbyl glucoside has been characterized by the inventors as being capable of inhibiting the black or brown colouration of the comedones and hence of preventing the appearance of the black or brown colour of the cutaneous blackhead. This is because, as emerges from the examples below, the inventors have found that ascorbyl glucoside inhibits the formation of cutaneous blackheads by probably intervening in the process of oxidation of L-DOPA (3,4-dihydroxy-L-phenylalanine). For the record, L-DOPA is involved in the very complex melanogenesis mechanism.
  • the oxidation of L-DOPA, promoted by the microbial activity present in the comedo is expressed by a colouring effect probably of dopachrome type, the latter being a coloured intermediate of the pathway for the biosynthesis of melanin.
  • the ascorbyl glucoside in accordance with the invention appears to impair the formation of the product of the oxidation reaction in the comedones and thus inhibits the black or brown colouration of the latter. This effectiveness of ascorbyl glucoside is, to the knowledge of the inventors, characterized for the first time.
  • ascorbyl glucoside is already used in care products, in particular in the patent FR 2 913 198 B 1, but for the most part as an antioxidant active agent intended to combat the cutaneous signs of ageing and in particular to maintain and/or restore the biomechanical properties of the skin.
  • compositions have already been proposed comprising ascorbyl glucoside in combination with phenanthrenol as active agents for the skin, for the purposes of depigmenting and/or whitening the latter, and thus for an effect very distinct from that found according to the invention, namely preventing the appearance of cutaneous blackheads by inhibiting the appearance of the brown or black colour in the comedones.
  • Patent application US 2006/057092 Al discloses a cosmetic use for the care of greasy skin of a composition comprising (a) a water-soluble ascorbic acid compound and (b) porous polyamide particles. This document merely focuses on treating greasy skin, and is thus silent regarding reducing and/or inhibiting the development of colour of cutaneous comedones. To the inventor, the porous polyamide particles should be responsible for the effect suggested therein on sebum excess.
  • the depigmentation of the skin is carried out by inhibition of the pathway for the biosynthesis of human melanin, in particular via the inhibition of the expression of tyrosinase, whereas the prevention of the brown or black colouration of the comedones is carried out, as mentioned above, by impairing the formation of dopachrome.
  • the term "inhibitor of the black or brown colouration of the comedones" is understood to denote, for the purposes of the present invention, a compound capable of slowing down, indeed even preventing, the appearance of the black or brown colour of the comedones.
  • a compound is considered an inhibitor of the black or brown colouration of the comedones if the percentage of inhibition with regard to the development of the colour is at least 15%, preferably at least 20%, more particularly at least 25%, in particular as evaluated according to the protocol detailed in the examples below.
  • the present invention relates to a cosmetic process for reducing and/or inhibiting the development of colour, for example brown or black colour, of cutaneous comedones, comprising the topical application to the skin of a cosmetic composition comprising ascorbyl glucoside.
  • the skin is the skin of the face and/or of the body, in particular of the face and/or of the hands, preferably of the face, and more particularly of the forehead and/or of the alae of the nose and/or of the chin.
  • the skin is greasy and/or shiny skin, in particular skin exhibiting secretion and excessive excretion of sebum.
  • the skin is in particular greasy and/or shiny skin, especially of phototype 1, 2, 3 or 4, in particular greasy and/or shiny skin of the face and/or of the hands, more particularly greasy and/or shiny skin of the forehead and/or of the alae of the nose and/or of the chin.
  • the skin is non-acneic skin, namely healthy skin devoid of the clinical manifestations of acne, namely acne lesions, such as the presence of numerous acne pimples. This is because blackheads constitute cutaneous imperfections of the skin, distinct from ailments of the skin, such as acne.
  • the blackhead is not an inflammatory lesion of the skin, in contrast to the lesions characteristic of acne.
  • FIG 1 represents a graph of the measurement of the optical density (OD) at 475 nm as a function of time for compositions 1 (containing Cutibacterium acnes extract at a concentration of 1.5 mg/ml), 2 (containing L-DOPA at a concentration of 125 mg/ml), and the reference composition (containing a combination of Cutibacterium acnes extract at a concentration of 1.5 mg/ml and L-DOPA at a concentration of 125 pg/ml).
  • the present invention relates to the cosmetic use of ascorbyl glucoside. [Chem 1]
  • corbyl glucoside is understood to mean the product of condensation of glucose, in D form, i.e. in the form of a- or b-glucopyranose or of a- or b-furanose, or in L form, with ascorbic acid, preferably in L form.
  • Ascorbyl glucoside is provided in particular by the company Hayashibara or by the company Macrocare under the name "Ascorbic acid glucoside" at a content of 100% active material. It is in reality the 2-O-a-D-glucopyranoside of L-ascorbic acid. This isomer is preferred for use in the context of the present invention.
  • 2-O-a-D-glucosyl-L-ascorbic acid also known under the name ascorbic acid 2-glucoside
  • ascorbic acid 2-glucoside is a compound made up of a molecule of D-glucose bonded to the hydroxyl group in the C2 position of L-ascorbic acid (vitamin C) by an a-glucosidic bond.
  • said ascorbyl glucoside is present in the cosmetic composition in a content ranging from 0.01% to 10% by weight, preferably from 0.1% to 5% by weight, better still from 0.2% to 5% by weight, relative to the total weight of the cosmetic composition.
  • the ascorbyl glucoside can be incorporated into a cosmetic composition intended for a topical application, in order to prevent the formation of cutaneous blackheads, in particular in order to inhibit the development of the black or brown colour of comedones.
  • the present invention is targeted at a cosmetic use in which at least the ascorbyl glucoside employed according to the invention is present in a cosmetic composition intended to prevent the black or brown colouration of comedones.
  • the ascorbyl glucoside employed according to the invention when it is present within a composition, can be formulated in a physiologically acceptable medium.
  • Such a medium is considered to be physiologically acceptable when it does not cause any tingling, tautness or discomfort unacceptable for the user.
  • a composition used according to the invention can be provided in any formulation form normally used in the cosmetics field.
  • aqueous or aqueous/alcoholic solution which is optionally gelled, of a dispersion of the lotion type, which is optionally a two-phase lotion, of an oil-in-water or water-in-oil or multiple emulsion, of an aqueous gel, of a dispersion of oils in an aqueous phase, in particular by means of spherules, it being possible for these spherules to be polymer particles or, better still, lipid vesicles of ionic and/or non-ionic type, or else in the form of a powder, of a serum, of a paste or of a flexible rod or also of a stick. It can be of solid, pasty or more or less fluid liquid consistency.
  • composition can comprise any constituent normally employed in the topical application and administration envisaged.
  • Mention may in particular be made of water, solvents, compounds forming a fatty phase which is liquid at ambient temperature, for example oils of mineral, animal and/or vegetable origin, waxes, in particular, pigments, fillers, surfactants, thickeners, gelling agents, preservatives and mixtures thereof in any proportions.
  • oils for example oils of mineral, animal and/or vegetable origin, waxes, in particular, pigments, fillers, surfactants, thickeners, gelling agents, preservatives and mixtures thereof in any proportions.
  • a composition according to the invention can advantageously be provided in the form of an emulsion, in particular obtained by dispersion of an aqueous phase in a fatty phase (W/O) or of a fatty phase in an aqueous phase (O/W), of liquid or semi-liquid consistency of the milk type, or of soft, semi- solid or solid consistency of the cream or gel type, or also of multiple emulsion (W/O/W or O/W/O).
  • W/O a fatty phase
  • O/W aqueous phase
  • a composition used according to the invention can advantageously comprise at least one fatty phase which is liquid at ambient temperature and atmospheric pressure.
  • a fatty phase can comprise at least one non-volatile ether oil having from 10 to 40 carbon atoms and/or at least one non-volatile monoester oil.
  • non-volatile oil is understood to denote an oil, the vapour pressure of which at ambient temperature and atmospheric pressure is non zero and less than 10 3 mmHg (0.13 Pa).
  • ethers having from 10 to 40 carbon atoms of dicaprylyl ether (CTFA name: Dicaprylyl ether).
  • the amount of fatty phase which is liquid at ambient temperature and atmospheric pressure present in the compositions according to the invention can range, for example, from 0.01% to 50% by weight and preferably from 0.1% to 30% by weight, relative to the total weight of the composition.
  • the emulsions according to the invention can comprise at least one emulsifier chosen from amphoteric, anionic, cationic or non-ionic emulsifiers, used alone or as a mixture.
  • the emulsifiers are appropriately chosen according to the emulsion to be obtained (W/O or O/W).
  • the emulsifiers are generally present in the composition in a proportion which can range from 0.3% to 30% by weight and preferably from 0.5% to 20% by weight, relative to the total weight of the composition.
  • examples of emulsifiers include non-ionic surfactants, and especially esters of polyols and of fatty acids with a saturated or unsaturated chain comprising, for example, from 8 to 24 carbon atoms and better still from 12 to 22 carbon atoms, and the oxyalkylenated derivatives thereof, i.e.
  • derivatives comprising oxyethylenated and/or oxypropylenated units, for example the glyceryl esters of C8-C24 fatty acids, and the oxyalkylenated derivatives thereof; the polyethylene glycol esters of C8-C24 fatty acids, and the oxyalkylenated derivatives thereof; the sorbitol esters of C8-C24 fatty acids, and the oxyalkylenated derivatives thereof; the sugar (sucrose, glucose or alkylglucose) esters of C8-C24 fatty acids, and the oxyalkylenated derivatives thereof; fatty alcohol ethers; the sugar ethers of C8-C24 fatty alcohols, and mixtures thereof in any proportions.
  • a composition according to the invention can additionally comprise at least one silicone elastomer, in particular the products sold under the KSG names by Shin-Etsu, under the Trefil, BY29 or EPSX names by Dow Coming or under the Gransil names by Grant Industries.
  • a composition used according to the invention can additionally contain one or more adjuvants commonly used in the cosmetics field, in particular sequestering agents, odour absorbers, UV-screening agents, fragrances, mattifying agents, and abrasive fillers or exfoliating agents, and mixtures thereof in any proportions.
  • adjuvants commonly used in the cosmetics field in particular sequestering agents, odour absorbers, UV-screening agents, fragrances, mattifying agents, and abrasive fillers or exfoliating agents, and mixtures thereof in any proportions.
  • composition used according to the invention can advantageously comprise at least one additional active agent.
  • It can in particular be at least one active agent for caring for greasy skin.
  • additional active agent is understood to mean, in the context of the present invention, a compound which has, by itself, that is to say not requiring the intervention of an external agent in order to activate it, a biological activity which can in particular be:
  • the additional active agent which can be used in the compositions of the invention is preferentially chosen from desquamating agents, soothing agents, anti-irritant agents, sebum-regulating or anti-seborrhoeic agents, astringent agents and mixtures thereof in any proportions.
  • the additional active agent for caring for greasy skin used in the composition according to the invention can represent from 0.0001% to 20%, preferably from 0.01% to 10% and better still from 0.01% to 5% by weight, relative to the total weight of the composition.
  • composition employed according to the invention can advantageously comprise from 5% to 80% by weight and preferably from 35% to 75% by weight of water, relative to the total weight of said composition.
  • the pH of said composition is advantageously less than or equal to 8, preferably ranging from 4 to 7, even better still ranging from 4.5 to 6.5.
  • a composition according to the invention can additionally comprise retinol, otherwise known as vitamin A, preferably all-trans-retinol.
  • a composition according to the invention can comprise an amount of retinol ranging from 0.02% to 5.0% by weight, in particular from 0.05% to 3.0% by weight, relative to the total weight of the composition.
  • composition employed according to the invention can comprise at least one additional active agent, in particular chosen from salicylic acid, hydroxypropyl tetrahydropyrantriol (pro-xylane), retinol and mixtures thereof.
  • additional active agent in particular chosen from salicylic acid, hydroxypropyl tetrahydropyrantriol (pro-xylane), retinol and mixtures thereof.
  • a composition according to the invention can additionally comprise at least one polyol, namely an organic molecule comprising at least two free hydroxyl groups, in particular chosen from ethylene glycol, propylene glycol, propane- 1,3-diol, 1,3-butylene glycol, isoprene glycol, 1,2-pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, glycerol, pentaerythritol, trimethylolpropane, polyglycerols, polyethylene glycols and mixtures thereof.
  • polyol namely an organic molecule comprising at least two free hydroxyl groups, in particular chosen from ethylene glycol, propylene glycol, propane- 1,3-diol, 1,3-butylene glycol, isoprene glycol, 1,2-pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, glycerol, pentaerythr
  • a composition according to the invention can additionally comprise at least one gelling agent, in particular a hydrophilic gelling agent, namely a compound capable of gelling the aqueous phase of the compositions according to the invention.
  • a hydrophilic gelling agent namely a compound capable of gelling the aqueous phase of the compositions according to the invention.
  • hydrophilic gelling agents of the polymers and copolymers of 2-acrylamido-2- methylpropanesulfonic acid, which are crosslinked and/or neutralized, polysaccharides and mixtures thereof.
  • a composition according to the invention can also comprise at least one derivative of polyethylene glycol and of mono-, di- and triglycerides of an acid comprising at least one alkyl chain ranging from Ce to C 1 ⁇ 2 , and having at least two ethylene oxide groups, in particular chosen from derivatives of polyethylene glycol and of mono-, di- and triglycerides of caprylic acid and of capric acid, for example that comprising 6 ethylene oxide groups (INCI name: PEG-6 caprylic/capric glycerides), sold under the name Softigen 767 by Sasol.
  • a composition according to the invention can also comprise at least one colourant chosen, for example, from pigments, pearlescent agents, dyes, effect materials and mixtures thereof in any proportions.
  • These colourants can be present in a content ranging from 0.01% to 50% by weight and preferably from 0.01% to 30% by weight, relative to the total weight of the composition.
  • a composition according to the invention can additionally comprise at least one filler, in particular in a content ranging from 0.01% to 50% by weight, preferably ranging from 0.01% to 30% by weight, relative to the total weight of the composition.
  • These fillers can be inorganic or organic and of any shape, platelet, spherical or oblong, whatever the crystallographic form (for example lamellar, cubic, hexagonal, orthorhombic or amorphous).
  • a composition of the invention can advantageously exhibit a firm and compact feel when taken up. It can be thick on application and subsequently be transformed, melt and release freshness.
  • composition of the invention can advantageously be provided in the form of a more or less wide stick, such as a pencil, for example.
  • a composition can alternatively have the form of a product for caring for or making up the face and/or the body, and be packaged, for example, in the form of cream in ajar or of fluid in a tube or as a pump-action bottle.
  • a composition according to the invention can be manufactured by any known process generally used in the cosmetics field.
  • the ingredients are mixed before they are shaped, in the order and under conditions which are easily determined by a person skilled in the art.
  • the present invention relates to a cosmetic process for preventing the black or brown colouration of comedones, comprising the topical application to the skin of a cosmetic composition comprising at least ascorbyl glucoside.
  • the cosmetic process of the invention is carried out by administering, by the topical route, a composition comprising at least ascorbyl glucoside according to the invention, preferably in a physiologically acceptable medium.
  • the topical administration consists of the external application to the skin of cosmetic compositions according to the usual techniques for use of these compositions.
  • the cosmetic process according to the invention can be carried out by topical application, for example daily, of at least ascorbyl glucoside in accordance with the invention, which can, for example, be formulated in the form of a cream, gel, serum, lotion, emulsion, make-up-removing milk, stick or aftersun composition.
  • the application is repeated, for example, 1 to 2 times daily for one day or more and generally over an extended period of at least 4 weeks, indeed even 4 to 15 weeks, with, if appropriate, one or more periods of interruption.
  • the application is daily (once per day) and generally over an extended period of at least 4 weeks, indeed even 4 to 15 weeks, with, if appropriate, one or more periods of interruption.
  • composition including at least ascorbyl glucoside as defined above will be applied to skin regions which have been cleansed beforehand, for example using an appropriate soap, and/or freed beforehand from at least one blackhead, for example using an adhesive patch or a mechanical action.
  • treatment combinations with optionally topical forms in order to complement or to reinforce the activity of the ascorbyl glucoside, can be envisaged.
  • the present descreiption also describes a cosmetic process for preventing the black or brown colouration of comedones, comprising: a) a step of topical application to the skin of a cosmetic composition comprising at least ascorbyl glucoside; and b) a step of topical application of a composition different from the composition applied in step a) and containing at least one active agent distinct from ascorbyl glucoside.
  • the present invention relates to a cosmetic process for preventing the black or brown colouration of comedones, comprising: a) a step of topical application to the skin of a cosmetic composition comprising at least ascorbyl glucoside, said ascorbyl glucoside being present therein in a content ranging from 0.01 to 10% by weight, relative to the total weight of said cosmetic composition; and b) a step of topical application of a composition different from the composition applied in step a) and containing at least one active agent distinct from ascorbyl glucoside.
  • said ascorbyl glucoside is present in the cosmetic composition applied during step a) in a content ranging from 0.1% to 5% by weight, preferably from 0.2 to 5% by weigh, relative to the total weight of the cosmetic composition.
  • the cosmetic composition applied during step a can be as defined hereabove.
  • Such a composition applied in step b) can be described as "supplementary composition”.
  • Steps a) and b) defined above can be carried out simultaneously or successively.
  • This supplementary composition which is different from the composition employed according to the invention, and applicable by the topical route, can in particular be in the form of an emulsified oil-in-water gel, comprising retinol; at least one polyol; at least one hydrophilic gelling agent; at least one derivative of polyethylene glycol and of mono-, di- and triglycerides of an acid comprising at least one alkyl chain ranging from Ce to C 1 ⁇ 2 , and having at least two ethylene oxide groups; at least one non-volatile ether oil having from 10 to 40 carbon atoms; and at least one non-volatile monoester oil.
  • dark-coloured structures is understood to denote the structures responsible for the colouration of blackheads.
  • This method is targeted at characterizing the change over time, in the expression of colour, brought about by an intracellular extract of bacteria of Cutibacterium acnes type (formerly listed under the name Propionibacterium acne ) in the presence of 3,4-dihydroxy-L- phenylalanine (L-DOPA), which extract is deposited at the surface of an EpiSkin TM reconstituted epidermis.
  • L-DOPA 3,4-dihydroxy-L- phenylalanine
  • an intracellular extract of bacteria of Cutibacterium acnes CIP 53.117 type is suspended in IX PBS (Dulbecco's Phosphate Buffered Saline, supplied by Gibco BRL, Life Technologies) at a concentration of 6 mg/ml.
  • IX PBS Dulbecco's Phosphate Buffered Saline, supplied by Gibco BRL, Life Technologies
  • This extract is subsequently deposited at the surface of an EpiSkin epidermis in the presence of 3,4- dihydroxy-L-phenylalanine (L-DOPA - supplied by Sigma- Aldrich) at 1 mg/ml.
  • This method is based on the measurement of absorbance, over time, carried out directly on a composition formed of a mixture of intracellular extract of bacteria of Cutibacterium acnes type, of 3,4-dihydroxy-L-phenylalanine (L-DOPA) and of the compound to be tested.
  • L-DOPA 3,4-dihydroxy-L-phenylalanine
  • the measurements are compared with those carried out for a mixture of an intracellular extract of bacteria of Cutibacterium acnes type and of 3,4-dihydroxy-L-phenylalanine (L- DOPA), in the absence of compound to be tested (reference).
  • L- DOPA 3,4-dihydroxy-L-phenylalanine
  • the method is adapted from a method for the enzymatic assay of the tyrosinase activity (Behbahani et al. , Microchemical Journal (1993), 47, 251), which is based on the absorbance properties at 475 nm of a coloured intermediate of the pathway for the biosynthesis of melanin starting from L-DOPA, namely dopachrome, a product of the oxidation of L-DOPA.
  • a solution of L-DOPA at a concentration of 0.5 mg/ml is prepared by bringing together L- DOPA (supplied by Sigma- Aldrich) and milliQ water, so as to have an L-DOPA concentration of 1 mg/ml, and then diluting with IX PBS (Dulbecco's Phosphate Buffered Saline, supplied by Gibco BRL, Life Technologies).
  • L- DOPA supplied by Sigma- Aldrich
  • IX PBS Dulbecco's Phosphate Buffered Saline, supplied by Gibco BRL, Life Technologies.
  • composition 1 comprising only a Cutibacterium acnes extract
  • the 6 mg/ml Cutibacterium acnes extract was diluted with IX PBS (Dulbecco's Phosphate Buffered Saline supplied by Gibco BRL, Life Technologies) so as to form a 200 m ⁇ composition with a concentration of 1.5 mg/ml of Cutibacterium acnes.
  • IX PBS Dulbecco's Phosphate Buffered Saline supplied by Gibco BRL, Life Technologies
  • composition 2 comprising only L-DOPA
  • the 0.5 mg/ml L-DOPA solution was also diluted with IX PBS (Dulbecco's Phosphate Buffered Saline supplied by Gibco BRL, Life Technologies) so as to form a 200 m ⁇ composition with a concentration of 125 pg/ml of L-DOPA.
  • IX PBS Dulbecco's Phosphate Buffered Saline supplied by Gibco BRL, Life Technologies
  • compositions to be tested and the reference composition are introduced separately into wells of a 96-well microplate suitable for reading in visible spectrophotometry, and placed at a temperature of 32°C.
  • the formation of a coloured product is then monitored over time by spectrophotometry.
  • the absorbance, or optical density (O.D.) is measured at 475 nm from the time 0 to the time 2 hours by means of a Spectra Max M5 e reader and the Spectra Max software (the time 0 corresponds to the addition of composition 1 or the introduction of the composition into the wells).
  • compositions 1 and 2 comprising solely a Cutibacterium acnes extract and solely L-DOPA, respectively. This confirms the catalytic activity of the bacterial extract of Cutibacterium acnes on the development of the dark colour by oxidation of L-DOPA.
  • the ability to inhibit the development of colour of a given compound was assessed by comparing the absorbance measurements obtained for the test compositions with those obtained for the reference composition.
  • the inhibitory effect of the compound to be tested was evaluated by comparing the initial rate of oxidation of the L-DOPA under the action of the bacterial extract at 475 nm for the test composition with that of the reference composition in order to obtain a corresponding percentage of inhibition.
  • the initial rate (Vi) of the oxidation reaction is calculated from the linear part of the curve of the graph of the absorbance values. As this part lies between 10 and 40 minutes (see the graph in Figure 1), the initial rate of the oxidation reaction is determined using the following relationship:
  • the percentage of inhibition (%inhib) of a given compound with regard to the formation of the coloured product is subsequently obtained using the values of the initial rate of the oxidation reaction for the reference composition (Vi ref ) and for the test composition (Vi test ) according to the following relationship:
  • a compound is considered to have an inhibitory effect if the %inhib value is at least 15%.
  • Example 1 In vitro evaluation of the ability of the ascorbyl glucoside to inhibit the development of the colour
  • Three test compositions, 1, 2, and 3, comprising ascorbyl glucoside, AG, (reference ASCORBYL GLUCOSIDE AA2G® supplied by Hayashibara) at respective concentrations of 0.125, 0.25 and 0.5 mg/ml were prepared.
  • These compositions, with a total volume of 200 pi also contain L-DOPA (25 pg), the Cutibacterium acnes extract (0.3 mg) and the PBS buffer which are mentioned in the methodology part above.
  • the change in the optical density at 475 nm of these three compositions, and also the reference composition is then measured according to the protocol indicated in the methodology part above.
  • the measured optical density values are collated in the following table.
  • Example 2 Cosmetic compositions comprising at least ascorbyl glucoside in accordance with the invention
  • composition for topical application which comprises:
  • composition applied to the skin makes it possible to prevent the black or brown colouration of the comedones.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation cosmétique d'ascorbyl glucoside pour réduire et/ou inhiber le développement de couleur, par exemple de couleur brune ou noire, de comédons. L'invention concerne également un procédé cosmétique correspondant qui comprend l'application topique sur la peau d'une composition cosmétique comprenant de l'ascorbyle glucoside à une teneur allant de 0,01 à 10 % en poids, par rapport au poids total de ladite composition cosmétique.
PCT/EP2022/064027 2021-05-28 2022-05-24 Utilisation d'ascorbyl glucoside pour prévenir la coloration de points noirs WO2022248459A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFR2105573 2021-05-28
FR2105573A FR3123210B1 (fr) 2021-05-28 2021-05-28 Utilisation de l’ascorbyl glucoside pour prévenir la coloration des points noirs cutanés.

Publications (1)

Publication Number Publication Date
WO2022248459A1 true WO2022248459A1 (fr) 2022-12-01

Family

ID=76807803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/064027 WO2022248459A1 (fr) 2021-05-28 2022-05-24 Utilisation d'ascorbyl glucoside pour prévenir la coloration de points noirs

Country Status (2)

Country Link
FR (1) FR3123210B1 (fr)
WO (1) WO2022248459A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540567A (en) 1976-10-15 1985-09-10 Lever Brothers Company Cosmetic composition
US6437002B1 (en) * 1998-05-15 2002-08-20 Showa Denko K.K. Agent for preventing and treating skin diseases
US20040234632A1 (en) * 2001-06-29 2004-11-25 Antoine Piccirilli Use of at least an oil extracted from the seeds of the gourd family for preparing a composition for inhibiting 5$g(a)-reductase activity
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060057092A1 (en) 2004-09-16 2006-03-16 L'oreal Cosmetic use of a composition including an ascorbic acid compound and polyamide particles
US20060100178A1 (en) * 1999-01-26 2006-05-11 Showa Denko K.K. Dermal agent
US20090018200A1 (en) 2007-07-12 2009-01-15 L'oreal Composition containing a phenanthrenol
FR2913198B1 (fr) 2007-03-01 2009-06-05 Oreal Utilisation cosmetique d'une association de biotine et de vitamine cg.
EP3150187A1 (fr) 2015-09-30 2017-04-05 Johnson & Johnson Consumer Inc. Compositions et procédés de traitement d'histomonose
CN111759750A (zh) * 2020-08-06 2020-10-13 苏州讯如电子科技有限公司 一种祛痘淡斑的水凝胶缓释面膜及其制备方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540567A (en) 1976-10-15 1985-09-10 Lever Brothers Company Cosmetic composition
US6437002B1 (en) * 1998-05-15 2002-08-20 Showa Denko K.K. Agent for preventing and treating skin diseases
US20060100178A1 (en) * 1999-01-26 2006-05-11 Showa Denko K.K. Dermal agent
US20040234632A1 (en) * 2001-06-29 2004-11-25 Antoine Piccirilli Use of at least an oil extracted from the seeds of the gourd family for preparing a composition for inhibiting 5$g(a)-reductase activity
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060057092A1 (en) 2004-09-16 2006-03-16 L'oreal Cosmetic use of a composition including an ascorbic acid compound and polyamide particles
FR2913198B1 (fr) 2007-03-01 2009-06-05 Oreal Utilisation cosmetique d'une association de biotine et de vitamine cg.
US20090018200A1 (en) 2007-07-12 2009-01-15 L'oreal Composition containing a phenanthrenol
EP3150187A1 (fr) 2015-09-30 2017-04-05 Johnson & Johnson Consumer Inc. Compositions et procédés de traitement d'histomonose
CN111759750A (zh) * 2020-08-06 2020-10-13 苏州讯如电子科技有限公司 一种祛痘淡斑的水凝胶缓释面膜及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEHBAHANI ET AL., MICROCHEMICAL JOURNAL, vol. 47, 1993, pages 251
DATABASE GNPD [online] MINTEL; 28 August 2019 (2019-08-28), ANONYMOUS: "Daily Ritual Anti-Aging Cleanser & Moisturizer Set", XP055886940, retrieved from https://www.gnpd.com/sinatra/recordpage/6818821/ Database accession no. 6818821 *

Also Published As

Publication number Publication date
FR3123210B1 (fr) 2023-12-15
FR3123210A1 (fr) 2022-12-02

Similar Documents

Publication Publication Date Title
AU2003303628B2 (en) Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
RU2170574C2 (ru) Способ и композиции для регенерации состарившейся кожи
US20230372221A1 (en) Use of thiopyridinone compounds for preventing the formation of cutaneous blackheads
JP7307835B2 (ja) 水性組成物
EP2370052B1 (fr) Nouvel agent inhibiteur de secretion de sebum
CN101394898A (zh) 葡聚糖组合物
US9452113B2 (en) Method for treating oily skin
JP2023165989A (ja) ざ瘡及び／又は過剰角質化に関連する状態の処置をする方法
JP2002363058A (ja) 敏感肌又は不耐性皮膚の許容限界を増大させるための少なくとも一のキレート剤を含む組成物の使用
WO2014173847A1 (fr) Huile essentielle de satureja montana présentant une teneur élevée en géraniol et utilisation pour le traitement d'une peau grasse et/ou des défauts esthétiques associés
EP1830794A2 (fr) Composition cosmetique, procede d'elaboration de cette composition et produit cosmetique
ES2548204T3 (es) Utilización de compuestos (etoxi-hidroxifenil)alquilcetona o etoxihidroxialquilfenol para tratar la piel grasa
US11918666B2 (en) Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment
KR101815340B1 (ko) 불로화 추출물을 유효성분으로 포함하는 조성물
FR3044905B1 (fr) Utilisation d'un antioxydant pour diminuer le developpement de la couleur des points noirs
WO2022248459A1 (fr) Utilisation d'ascorbyl glucoside pour prévenir la coloration de points noirs
US20200046617A1 (en) Composition For Combating The Signs Of Ageing Of The Skin And Hair And Nails
FR3013980A1 (fr) Composition a base d'eau de mer et d'extraits d'algues a activite anti-vieillissement cutane
KR100364314B1 (ko) 탈색제로서 미발효된 당밀의 용도
WO2023156588A1 (fr) Utilisation de rhamnolipides pour prévention de la coloration de comédons cutanés
WO2022268755A1 (fr) Utilisation d'une composition cosmétique pour la prévention et/ou le traitement de points noirs cutanés
JP6823938B2 (ja) 皮膚外用剤
CN114681344A (zh) 一种含有植物干细胞且能够嫩肤和祛皱的皮肤修护乳
HU221141B1 (en) Composition for cellulite treatments and process for its preparation
JPH09278641A (ja) 皮膚化粧料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22730444

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22730444

Country of ref document: EP

Kind code of ref document: A1